Metabolic alterations in cancer cells and therapeutic implications

Cancer metabolism has emerged as an important area of research in recent years. Elucidation of the metabolic differences between cancer and normal cells and the underlying mechanisms will not only advance our understanding of fundamental cancer cell biology but also provide an important basis for the development of new therapeutic strategies and novel compounds to selectively eliminate cancer cells by targeting their unique metabolism. This article reviews several important metabolic alterations in cancer cells, with an emphasis on increased aerobic glycolysis (the Warburg effect) and glutamine addiction, and discusses the mechanisms that may contribute to such metabolic changes. In addition, metabolic alterations in cancer stem cells, mitochondrial metabolism and its influence on drug sensitivity, and potential therapeutic strategies and agents that target cancer metabolism are also discussed.

[1]  J. Tamburini,et al.  LKB1/AMPK/mTOR signaling pathway in hematological malignancies: From metabolism to cancer cell biology , 2011, Cell cycle.

[2]  G. Schatten,et al.  Energy Metabolism in Human Pluripotent Stem Cells and Their Differentiated Counterparts , 2011, PloS one.

[3]  Nicholas B. Griner,et al.  Mitochondrial Dysfunction Impairs Tumor Suppressor p53 Expression/Function* , 2011, The Journal of Biological Chemistry.

[4]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[5]  T. Mak,et al.  Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.

[6]  M. Berardi,et al.  Survival of the fittest: metabolic adaptations in cancer. , 2011, Current opinion in genetics & development.

[7]  J. Erickson,et al.  Glutaminase: A Hot Spot For Regulation Of Cancer Cell Metabolism? , 2010, Oncotarget.

[8]  Laura A. Sullivan,et al.  Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. , 2010, Cancer research.

[9]  T. Seyfried,et al.  Glutamine targeting inhibits systemic metastasis in the VM‐M3 murine tumor model , 2010, International journal of cancer.

[10]  D. Dang,et al.  Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genes , 2010, Molecular Cancer.

[11]  C. Dang,et al.  Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. , 2010, Cancer cell.

[12]  J. Tamburini,et al.  Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies , 2010, Leukemia.

[13]  C. Thompson,et al.  Glutamine addiction: a new therapeutic target in cancer. , 2010, Trends in biochemical sciences.

[14]  H. Xin,et al.  Targeting glutamine metabolism sensitizes melanoma cells to TRAIL-induced death. , 2010, Biochemical and biophysical research communications.

[15]  Qicheng Ma,et al.  Activation of a metabolic gene regulatory network downstream of mTOR complex 1. , 2010, Molecular cell.

[16]  T. Tsuruo,et al.  Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment , 2010, Cell Death and Differentiation.

[17]  A. Levine,et al.  The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. , 2010, Trends in cell biology.

[18]  W. Wheaton,et al.  Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity , 2010, Proceedings of the National Academy of Sciences.

[19]  Mengwei Zang,et al.  AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. , 2010, Future oncology.

[20]  A. Chou,et al.  Immunohistochemistry for SDHB Divides Gastrointestinal Stromal Tumors (GISTs) into 2 Distinct Types , 2010, The American journal of surgical pathology.

[21]  L. Alberghina,et al.  Mitochondrial Complex I decrease is responsible for bioenergetic dysfunction in K-ras transformed cells. , 2010, Biochimica et biophysica acta.

[22]  G. Semenza.  HIF-1: upstream and downstream of cancer metabolism. , 2010, Current opinion in genetics & development.

[23]  Peng Huang,et al.  Small mitochondria-targeting molecules as anti-cancer agents. , 2010, Molecular aspects of medicine.

[24]  G. Brewer,et al.  Impairment of mitochondrial respiration in mouse fibroblasts byoncogenic H-RASQ61L , 2010, Cancer biology & therapy.

[25]  King-Jen Chang,et al.  Multiple Lineages of Human Breast Cancer Stem/Progenitor Cells Identified by Profiling with Stem Cell Markers , 2009, PloS one.

[26]  M. Nikiforova,et al.  Diagnostic Use of IDH1/2 Mutation Analysis in Routine Clinical Testing of Formalin-Fixed, Paraffin-Embedded Glioma Tissues , 2009, Journal of neuropathology and experimental neurology.

[27]  J. Engh,et al.  Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α , 2009, Oncogene.

[28]  Guido Nikkhah,et al.  NOTCH Pathway Blockade Depletes CD133‐Positive Glioblastoma Cells and Inhibits Growth of Tumor Neurospheres and Xenografts , 2009, Stem cells.

[29]  C. Dang,et al.  MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities , 2009, Clinical Cancer Research.

[30]  Zhigang Xie.  Brain Tumor Stem Cells , 2009, Neurochemical Research.

[31]  Philip R Quinlan,et al.  Histological evaluation of AMPK signalling in primary breast cancer , 2009, BMC Cancer.

[32]  R. Shaw,et al.  The LKB1–AMPK pathway: metabolism and growth control in tumour suppression , 2009, Nature Reviews Cancer.

[33]  Funda Meric-Bernstam,et al.  Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Peng Huang,et al.  Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? , 2009, Nature Reviews Drug Discovery.

[35]  Hui Wang,et al.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. , 2009, Cancer cell.

[36]  M. Wicha,et al.  Regulation of Mammary Stem/Progenitor Cells by PTEN/Akt/β-Catenin Signaling , 2009, PLoS biology.

[37]  T. Taguchi,et al.  Stem cell marker aldehyde dehydrogenase 1‐positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression , 2009, Cancer science.

[38]  Ping Chen,et al.  Selective apoptosis induction by the cancer chemopreventive agent N-(4-hydroxyphenyl)retinamide is achieved by modulating mitochondrial bioenergetics in premalignant and malignant human prostate epithelial cells , 2009, Apoptosis.

[39]  Peng Huang,et al.  Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate. , 2009, Biochimica et biophysica acta.

[40]  D. Guertin,et al.  The Pharmacology of mTOR Inhibition , 2009, Science Signaling.

[41]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[42]  Jeffrey P. MacKeigan,et al.  Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy , 2009, Cell.

[43]  A. Jakubowska,et al.  A range of cancers is associated with the rs6983267 marker on chromosome 8. , 2008, Cancer research.

[44]  E. Flescher,et al.  PI3K/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate toward sarcoma cells. , 2008, Neoplasia.

[45]  Gerald C. Chu,et al.  P53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation , 2008, Nature.

[46]  A. Lane,et al.  Targeting aspartate aminotransferase in breast cancer , 2008, Breast Cancer Research.

[47]  Yang Liu,et al.  TSC–mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species , 2008, The Journal of experimental medicine.

[48]  Dexin Kong,et al.  Phosphatidylinositol 3‐kinase inhibitors: promising drug candidates for cancer therapy , 2008, Cancer science.

[49]  W. Plunkett,et al.  Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. , 2008, Blood.

[50]  D. Carling,et al.  The regulation of AMP-activated protein kinase by upstream kinases , 2008, International Journal of Obesity.

[51]  V. Shoshan-Barmatz,et al.  Methyl jasmonate binds to and detaches mitochondria-bound hexokinase , 2008, Oncogene.

[52]  S. Fröhling,et al.  Deregulation of signaling pathways in acute myeloid leukemia. , 2008, Seminars in oncology.

[53]  Guido Kroemer,et al.  Tumor cell metabolism: cancer's Achilles' heel. , 2008, Cancer cell.

[54]  R. Abraham,et al.  A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. , 2008, Cancer research.

[55]  S. Sollott,et al.  Hexokinase II Detachment from Mitochondria Triggers Apoptosis through the Permeability Transition Pore Independent of Voltage-Dependent Anion Channels , 2008, PloS one.

[56]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[57]  Christopher J Schofield,et al.  Expanding chemical biology of 2-oxoglutarate oxygenases. , 2008, Nature chemical biology.

[58]  Utpal Banerjee,et al.  Distinct mitochondrial retrograde signals control the G1-S cell cycle checkpoint , 2008, Nature Genetics.

[59]  Ralph J Deberardinis,et al.  Brick by brick: metabolism and tumor cell growth. , 2008, Current opinion in genetics & development.

[60]  John O Trent,et al.  Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth , 2008, Molecular Cancer Therapeutics.

[61]  P. Mack,et al.  Inhibition of Akt pathways in the treatment of prostate cancer , 2007, Prostate Cancer and Prostatic Diseases.

[62]  G. Semenza,et al.  Hypoxia-Inducible Factor 1 (HIF-1) Pathway , 2007, Science's STKE.

[63]  G. Semenza,et al.  Hypoxia-Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1 , 2007, Molecular and Cellular Biology.

[64]  M. Oren,et al.  Living with p53, Dying of p53 , 2007, Cell.

[65]  Ø. Bruserud,et al.  Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling , 2007, Expert opinion on therapeutic targets.

[66]  J. Cleveland,et al.  Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. , 2007, Blood.

[67]  A. Hamosh,et al.  Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. , 2007, The New England journal of medicine.

[68]  P. Zancan,et al.  Clotrimazole inhibits and modulates heterologous association of the key glycolytic enzyme 6-phosphofructo-1-kinase. , 2007, Biochemical pharmacology.

[69]  R. Deberardinis,et al.  The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. , 2007, Genes & development.

[70]  S. Kondo,et al.  Inhibition of glycolysis: a novel strategy to overcome drug resistance in CD133+ tumor initiating cells under hypoxic microenvironment , 2007 .

[71]  P. Pedersen.  The cancer cell’s “power plants” as promising therapeutic targets: An overview , 2007, Journal of bioenergetics and biomembranes.

[72]  D. Spitz,et al.  2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. , 2007, Cancer research.

[73]  Saroj P. Mathupala,et al.  Lactate and malignant tumors: A therapeutic target at the end stage of glycolysis , 2007, Journal of bioenergetics and biomembranes.

[74]  S. S. Kanwar,et al.  Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. , 2007, Critical reviews in oncology/hematology.

[75]  Emma Saavedra,et al.  Energy metabolism in tumor cells , 2007, The FEBS journal.

[76]  Y. Shiratori,et al.  Gene expressions associated with chemosensitivity in human hepatoma cells. , 2007, Hepato-gastroenterology.

[77]  N. Sang,et al.  Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation. , 2007, Cancer research.

[78]  M. Wangpaichitr,et al.  Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-d-glucose , 2007, Molecular Cancer Therapeutics.

[79]  W. Sadee,et al.  Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia , 2007, Cancer Chemotherapy and Pharmacology.

[80]  A. Harris,et al.  Role of hypoxia-inducible factor-1alpha as a cancer therapy target. , 2006, Endocrine-related cancer.

[81]  Jinsong Liu,et al.  Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. , 2006, Cancer cell.

[82]  D. Cutler,et al.  An oligonucleotide microarray for high-throughput sequencing of the mitochondrial genome. , 2006, The Journal of molecular diagnostics : JMD.

[83]  Lilia Alberghina,et al.  Expression of transforming K-Ras oncogene affects mitochondrial function and morphology in mouse fibroblasts. , 2006, Biochimica et biophysica acta.

[84]  J. Chesney.  6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis , 2006, Current opinion in clinical nutrition and metabolic care.

[85]  S. Ohta,et al.  Contribution of somatic mutations in the mitochondrial genome to the development of cancer and tolerance against anticancer drugs , 2006, Oncogene.

[86]  H. Pelicano,et al.  Glycolysis inhibition for anticancer treatment , 2006, Oncogene.

[87]  J. Whitesides,et al.  Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[88]  Eyal Gottlieb,et al.  TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.

[89]  E. Araki,et al.  AMPK and cell proliferation – AMPK as a therapeutic target for atherosclerosis and cancer , 2006, The Journal of physiology.

[90]  Oksana Gavrilova,et al.  p53 Regulates Mitochondrial Respiration , 2006, Science.

[91]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[92]  N. Denko,et al.  HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. , 2006, Cell metabolism.

[93]  Ø. Bruserud,et al.  Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML , 2006, Expert opinion on therapeutic targets.

[94]  A. Adjei,et al.  K-ras as a target for cancer therapy. , 2005, Biochimica et biophysica acta.

[95]  J. Hoek,et al.  Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. , 2005, Cancer research.

[96]  J. Testa,et al.  AKT signaling in normal and malignant cells , 2005, Oncogene.

[97]  Eyal Gottlieb,et al.  Mitochondrial tumour suppressors: a genetic and biochemical update , 2005, Nature Reviews Cancer.

[98]  Y. Pu,et al.  Resistance to paclitaxel is proportional to cellular total antioxidant capacity. , 2005, Cancer research.

[99]  C. Chi,et al.  Mitochondrial DNA mutations and mitochondrial DNA depletion in gastric cancer , 2005, Genes, chromosomes & cancer.

[100]  N. Hay,et al.  The Akt-mTOR tango and its relevance to cancer. , 2005, Cancer cell.

[101]  B. Fuchs,et al.  Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? , 2005, Seminars in cancer biology.

[102]  T. Lazar Mathew,et al.  Optimizing Cancer Radiotherapy with 2-Deoxy-D-Glucose , 2005, Strahlentherapie und Onkologie.

[103]  J R Griffiths,et al.  Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. , 2005, Human molecular genetics.

[104]  G. Broggi,et al.  Instability of mitochondrial DNA and MRI and clinical correlations in malignant gliomas , 2005, Journal of Neuro-Oncology.

[105]  R. Deberardinis,et al.  The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid β-oxidation , 2005, Oncogene.

[106]  Vasilis Vasiliou,et al.  Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family , 2005, Human Genomics.

[107]  Massimo Zeviani,et al.  Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. , 2005, Cell metabolism.

[108]  P. Schumacker,et al.  Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. , 2005, Cell metabolism.

[109]  C. Arteaga,et al.  Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies. , 2005, Cancer research.

[110]  D. Harrison,et al.  Mitochondrial D-loop mutations and deletion profiles of cancerous and noncancerous liver tissue in hepatitis B virus-infected liver , 2005, British Journal of Cancer.

[111]  J. Best,et al.  Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer , 2005, Journal of cellular physiology.

[112]  P. Zhou,et al.  Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo , 2005, British journal of haematology.

[113]  J. Dancey.  Inhibitors of the mammalian target of rapamycin , 2005, Expert opinion on investigational drugs.

[114]  C. Esslinger,et al.  Ngamma-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site. , 2005, Bioorganic & medicinal chemistry.

[115]  N. Ruderman,et al.  AMPK, the metabolic syndrome and cancer. , 2005, Trends in pharmacological sciences.

[116]  Peng Huang,et al.  Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. , 2005, Cancer research.

[117]  Chao-yuan Huang,et al.  Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide , 2004, Anti-cancer drugs.

[118]  A. Alavi,et al.  Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.

[119]  Peng Huang,et al.  ROS stress in cancer cells and therapeutic implications. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[120]  M. Prentki,et al.  AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome , 2004, Nature Reviews Drug Discovery.

[121]  I. Chang,et al.  Resistance of Mitochondrial DNA-depleted Cells against Cell Death , 2004, Journal of Biological Chemistry.

[122]  Awtar Krishan,et al.  Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic conditions , 2004, Cancer Chemotherapy and Pharmacology.

[123]  N. Savaraj,et al.  2-Deoxy-d-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo , 2004, Cancer Research.

[124]  H. Uramoto,et al.  Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. , 2003, Cancer treatment reviews.

[125]  Laura C. Greaves,et al.  Mitochondrial DNA mutations in human colonic crypt stem cells. , 2003, The Journal of clinical investigation.

[126]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[127]  B. Dutrillaux,et al.  Phase II Study of Lonidamine and Diazepam in the Treatment of Recurrent Glioblastoma Multiforme , 2003, Journal of Neuro-Oncology.

[128]  M. Sanchez-Cespedes.  Mitochondrial DNA alterations in human tumors , 2003, Revista de Oncología.

[129]  N. Savaraj,et al.  Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). , 2002, Biochemical pharmacology.

[130]  Peng Huang,et al.  Mitochondrial defects in cancer , 2002, Molecular Cancer.

[131]  P. Bruzzi,et al.  Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  Saroj P. Mathupala,et al.  Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. , 2002, Biochimica et biophysica acta.

[133]  K. Inoki,et al.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.

[134]  D. Sabatini,et al.  mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.

[135]  J. Avruch,et al.  Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.

[136]  Luca Scorrano,et al.  A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. , 2002, Cancer cell.

[137]  P. Soares,et al.  Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors. , 2002, The American journal of pathology.

[138]  A. Paetau,et al.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer , 2002, Nature Genetics.

[139]  Lee-Jun C Wong,et al.  Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. , 2002, Cancer research.

[140]  Douglas C. Wallace,et al.  Accumulation of mitochondrial DNA deletions in the malignant prostate of patients of different ages , 2001, Experimental Gerontology.

[141]  Saroj P. Mathupala,et al.  Glucose Catabolism in Cancer Cells , 2001, The Journal of Biological Chemistry.

[142]  E Gabrielson,et al.  Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. , 2001, Cancer research.

[143]  S. Nomoto,et al.  Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. , 2001, Cancer research.

[144]  A. Levitzki,et al.  Enhanced ROS Production in Oncogenically Transformed Cells Potentiates c-Jun N-Terminal Kinase and p38 Mitogen-Activated Protein Kinase Activation and Sensitization to Genotoxic Stress , 2001, Molecular and Cellular Biology.

[145]  A. Cheung,et al.  High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. , 2001, Cancer research.

[146]  N. Savaraj,et al.  Hypersensitization of tumor cells to glycolytic inhibitors. , 2001, Biochemistry.

[147]  A. Tamori,et al.  Somatic mutation of mitochondrial DNA in cancerous and noncancerous liver tissue in individuals with hepatocellular carcinoma. , 2001, Cancer research.

[148]  M. Guida,et al.  Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. , 2001, European journal of cancer.

[149]  B. Zhivotovsky,et al.  Separation of cytochrome c-dependent caspase activation from thiol-disulfide redox change in cells lacking mitochondrial DNA. , 2000, Free radical biology & medicine.

[150]  C. Dang,et al.  Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc* , 2000, The Journal of Biological Chemistry.

[151]  K. Lillehei,et al.  A threshold concept for cancer therapy. , 2000, Medical hypotheses.

[152]  J. Jen,et al.  Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. , 2000, Science.

[153]  B. Devlin,et al.  Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. , 2000, Science.

[154]  Keshav K. Singh,et al.  Mitochondrial DNA determines the cellular response to cancer therapeutic agents , 1999, Oncogene.

[155]  M. Rinaldi,et al.  The Role of Vindesine and Lonidamine in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer: A Phase III Randomized Fonicap Trial , 1999, Tumori.

[156]  R. Bucala,et al.  An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[157]  Bert Vogelstein,et al.  Somatic mutations of the mitochondrial genome in human colorectal tumours , 1998, Nature Genetics.

[158]  T. Bruno,et al.  Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism. , 1998, Biochemical pharmacology.

[159]  Samuel Singer,et al.  Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.

[160]  J. Avruch,et al.  Amino Acid Sufficiency and mTOR Regulate p70 S6 Kinase and eIF-4E BP1 through a Common Effector Mechanism* , 1998, The Journal of Biological Chemistry.

[161]  R A Jungmann,et al.  c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[162]  G. Kroemer,et al.  Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death , 1995, The Journal of experimental medicine.

[163]  D. Samid,et al.  Phase I study of phenylacetate administered twice daily to patients with cancer , 1995, Cancer.

[164]  G. Attardi,et al.  Complementation and segregation behavior of disease-causing mitochondrial DNA mutations in cellular model systems. , 1995, Biochimica et biophysica acta.

[165]  J. C. Aledo,et al.  Phosphate‐activated glutaminase expression during tumor development , 1994, FEBS letters.

[166]  M. Guppy,et al.  The role of the Crabtree effect and an endogenous fuel in the energy metabolism of resting and proliferating thymocytes. , 1993, European journal of biochemistry.

[167]  J. Hayashi,et al.  Recovery of the missing tumorigenicity in mitochondrial DNA-less HeLa cells by introduction of mitochondrial DNA from normal human cells , 1992, Somatic cell and molecular genetics.

[168]  J. Hayashi,et al.  Introduction of disease-related mitochondrial DNA deletions into HeLa cells lacking mitochondrial DNA results in mitochondrial dysfunction. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[169]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[170]  S. Brusilow,et al.  Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. , 1988, The American journal of medicine.

[171]  K. Brand.  Glutamine and glucose metabolism during thymocyte proliferation. Pathways of glutamine and glutamate metabolism. , 1985, The Biochemical journal.

[172]  A. Lehninger,et al.  The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme. , 1984, The Journal of biological chemistry.

[173]  B. Silvestrini,et al.  Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. , 1981, Cancer research.

[174]  F. Sanger,et al.  Sequence and organization of the human mitochondrial genome , 1981, Nature.

[175]  B. Silvestrini,et al.  Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. , 1981, Journal of the National Cancer Institute.

[176]  F M Muggia,et al.  Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice. , 1979, Cancer research.

[177]  Ming-chi Wu,et al.  Mechanism of sensitivity of cultured pancreatic carcinoma to asparaginase , 1978, International journal of cancer.

[178]  P. Pedersen,et al.  High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[179]  J. Foker,et al.  Aerobic glycolysis during lymphocyte proliferation , 1976, Nature.

[180]  D. Roos,et al.  Changes in the carbohydrate metabolism of mitogenically stimulated human peripheral lymphocytes. II. Relative importance of glycolysis and oxidative phosphorylation on phytohaemagglutinin stimulation. , 1973, Experimental cell research.

[181]  I. A. Rose,et al.  Mitochondrial hexokinase. Release, rebinding, and location. , 1967, The Journal of biological chemistry.

[182]  S. Colowick,et al.  THE ROLE OF GLYCOLYSIS IN THE GROWTH OF TUMOR CELLS. 3. LACTIC DEHYDROGENASE AS THE SITE OF ACTION OF OXAMATE ON THE GROWTH OF CULTURED CELLS. , 1965, The Journal of biological chemistry.

[183]  P. Mitchell.  Coupling of Phosphorylation to Electron and Hydrogen Transfer by a Chemi-Osmotic type of Mechanism , 1961, Nature.

[184]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[185]  H. Eagle,et al.  Nutrition needs of mammalian cells in tissue culture. , 1955, Science.

[186]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.

[187]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[188]  P. Bottoni,et al.  Glycolytic enzyme inhibitors in cancer treatment. , 2008, Expert opinion on investigational drugs.

[189]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.

[190]  Min Wu,et al.  Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. , 2007, American journal of physiology. Cell physiology.

[191]  Sébastien Bonnet,et al.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. , 2007, Cancer cell.

[192]  J. Bos.  ras Oncogenes in Human Cancer: A Review1 , 2006 .

[193]  Eyal Gottlieb,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[194]  Michael Lehrke,et al.  The many faces of PPARgamma. , 2005, Cell.

[195]  E. Panosyan,et al.  Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase Formulations , 2005, Clinical pharmacokinetics.

[196]  G. Semenzato.  TARGETING HIF-1 FOR CANCER THERAPY , 2003 .

[197]  G. Owen,et al.  Glucose transporters: expression, regulation and cancer. , 2002, Biological research.

[198]  G. Parmigiani,et al.  Advances in Brief Detection of Mitochondrial DNA Mutations in Pancreatic Cancer Offers a “ Mass ”-ive Advantage over Detection of Nuclear DNA Mutations 1 , 2001 .

[199]  K. Tew,et al.  Cellular thiols and reactive oxygen species in drug-induced apoptosis. , 2001, The Journal of pharmacology and experimental therapeutics.

[200]  A. Alonso,et al.  Detection of somatic mutations in the mitochondrial DNA control region of colorectal and gastric tumors by heteroduplex and single‐strand conformation analysis , 1997, Electrophoresis.

[201]  E. Hamilton,et al.  Modification of tumour glucose metabolism for therapeutic benefit. , 1995, Acta oncologica.

[202]  T. N. Palmer,et al.  The role of glutamine and glucose analogues in metabolic inhibition of human myeloid leukaemia in vitro. , 1993, The International journal of biochemistry.

[203]  J. Grem,et al.  Metabolism and action of amino acid analog anti-cancer agents. , 1990, Pharmacology & therapeutics.

[204]  G. Attardi.  Animal mitochondrial DNA: an extreme example of genetic economy. , 1985, International review of cytology.

[205]  S. Weinhouse.  On respiratory impairment in cancer cells. , 1956, Science.